Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on Friday.
Investors seemed enthused …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Rising healthcare expenditure, growing geriatric population, increasing incidence of chronic diseases, patent expiration of blockbuster drugs, and increased consumption of generic drugs have created opportunities
Share this article LimmaTech will utilise the additional funds to expedite the preclinical and clinical development of its vaccine candidate pipeline. Credit: BaLL LunLa /
TerXT is a combination of xanomeline and trospium prodrugs for the treatment of schizophrenia, and intends to pursue accelerated 505(b)(2) approval pathway Miami, FL –